EVUSHELD: Protection for the Immunocompromised

EVUSHELD (tixagevimab & cilgavimab) is designed to offer protection from COVID-19 infections in patients who cannot mount an adequate immune response from COVID-19 vaccination (or for patients who cannot receive the vaccine for medical reasons).

EVUSHELD is specifically designed for patients that are immunocompromised.  Medical conditions or treatments that may result in moderate to severe immune compromise and an inadequate immune response to COVID-19 vaccination include but are not limited to:

  •  Active treatment for solid tumor and hematologic malignancies
  • Receipt of solid-organ transplant and taking immunosuppressive therapy
  • Receipt of chimeric antigen receptor (CAR)-T-cell or hematopoietic stem cell transplant (within 2 years of transplantation or taking immunosuppression therapy)
  • Moderate or severe primary immunodeficiency (e.g., DiGeorge syndrome, Wiskott-Aldrich syndrome)
  • Advanced or untreated HIV infection (people with HIV and CD4 cell counts <200/mm3, history of an AIDS-defining illness without immune reconstitution, or clinical manifestations of symptomatic HIV)
  • Active treatment with high-dose corticosteroids (i.e., ≥20 mg prednisone or equivalent per day when administered for ≥2 weeks), alkylating agents, antimetabolites,  transplant-related immunosuppressive drugs, cancer chemotherapeutic agents classified as severely immunosuppressive, tumor-necrosis (TNF) blockers, and other biologic agents that are immunosuppressive or immunomodulatory (e.g., B-cell depleting agents)

Want an EVUSHELD injection?  Fill out the form below:

Who is eligible for EVUSHELD?

Patients who receive EVUSHELD must be at least 12 years of age and weigh 40 kg or more.

Patients that are undergoing cancer treatment or are taking medications for treatment of Multiple Sclerosis (MS), Rheumatoid Arthritis, Crohn’s Disease, and to prevent organ transplant rejection all qualify.

Medications for MS include:

  • Ocrevus (ocrelizumab)
  • Kesimpta (ofatumumab)
  • Aubagio (teriflunomide)
  • Tysabri (natalizumab)
  • Lemtrada (alemtuzumab)

Medications that are TNF inhibitors that would qualify include:

  • Enbrel (etanercept)
  • Remicade (infliximab)
  • Humira (adalimumab)
  • Cimzia (certolizumab pegol)
  • Simponi (golimumab)

Medications commonly used for transplant rejection:

  • Prograf (tacrolimus)
  • Neoral (cyclosporine)
  • Imuran (azathioprine)
  • Rapamune (sirolimus, rapamycin)
  • Cellcept (mycophenolate mofetil)

If you are unsure whether you qualify or not, please do not hesitate to fill out the above form and we will have one of our providers contact you to discuss.

Learn more by watching our videos below:

Contact Aspira Health to schedule an appointment to discuss Covid 19 preventative options with your primary care doctor. Follow us on Facebook  and/or Instagram to get updates as they become available to our community in Southern Delaware.

Learn more about the Covid 19 Treatment options available through Aspira Health >

Previous Article

0 New comments

Leave a Reply

Your email address will not be published.

Latest News and Clinic Information

We are your partner in health. Stay up to date with latest news and information.

Evusheld Monoclonal Antibody Treatment Now Available

Aspira Health has been authorized to give the monoclonal antibody; Evusheld.  Learn more about Evusheld in this article. Schedule an appointment with Aspira Health to learn more about getting a prescription for the monoclonal antibody; Evusheld.

Read More

Premier Telehealth Coming to Southern Delaware 4/1

As a premier healthcare provider in Southern Delaware, Aspira Health is releasing a mobile app  that will include a suite of robust telemedicine features to enrich and enhance patients’ access to healthcare. The new mobile application builds upon Aspira Health’s commitment towards integrating their exceptional care with more modern and innovative solutions for the local community.
Read More

Treatment for Patients with Covid

Monoclonals for COVID Treatment – Now Available at Aspira

Read More